| Date | Research Question / Title | Unique ID | Research Team |
|---|---|---|---|
| January 22, 2021 | What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? [Update] | EOC062201v2 RR | EOC |
| May 19, 2020 | What are the risk factors for severity and death associated with COVID-19? | EPM050901 RR | Epidemiology & Modelling |
| May 19, 2020 | What is the relationship between antibody development and viral shedding and infectiousness? [Update] | LAB041601v2 RR | Laboratory |
| May 8, 2020 | What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update] | LAB040701v2 RR | Laboratory |
| April 15, 2020 | At what time in the disease timeline of COVID-19 do antibodies develop? | LAB041402 RR | Laboratory |
| April 11, 2020 | Is the IgM or IgG immune response protective? | LAB040803 RR | Laboratory |
